OncoTherapy Science, Inc. Logo

OncoTherapy Science, Inc.

Develops targeted cancer therapies and provides TCR repertoire analysis services.

4564 | T

Overview

Corporate Details

ISIN(s):
JP3202150003
LEI:
Country:
Japan
Address:
川崎市川崎区東田町1番地2
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

OncoTherapy Science, Inc. is a biotechnology company focused on the research and development of novel cancer treatments. Founded in 2001, the company collaborates with genomics pioneer Professor Yusuke Nakamura to identify cancer-specific genes for the creation of molecular-targeted therapies, including low-molecular-weight drugs and antibody drugs. The company's mission is to develop treatments with high efficacy and minimal adverse events. In addition to its drug discovery pipeline, OncoTherapy Science offers a comprehensive T-cell receptor (TCR) repertoire analysis service, utilizing next-generation sequencing technology for detailed immunoprofiling from blood and tissue samples.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 07:32
Registration Form
有価証券届出書(組込方式)
Japanese 399.0 KB
2025-11-10 01:21
Registration Form
確認書
Japanese 8.2 KB
2025-11-10 01:20
Interim Report
半期報告書-第25期(2025/04/01-2026/03/31)
Japanese 250.0 KB
2025-06-26 03:49
Post-Annual General Meeting Information
臨時報告書
Japanese 21.9 KB
2025-06-24 09:11
Governance Information
内部統制報告書-第24期(2024/04/01-2025/03/31)
Japanese 22.8 KB
2025-06-24 09:10
Registration Form
確認書
Japanese 8.2 KB
2025-06-24 09:09
Annual Report
有価証券報告書-第24期(2024/04/01-2025/03/31)
Japanese 976.0 KB
2025-04-10 08:33
Registration Form
有価証券届出書(組込方式)
Japanese 404.8 KB
2025-02-18 01:06
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2024-11-11 01:25
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-11 01:23
Interim Report
半期報告書-第24期(2024/04/01-2025/03/31)
Japanese 272.5 KB
2024-06-28 08:58
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB
2024-06-25 09:30
Governance Information
内部統制報告書-第23期(2023/04/01-2024/03/31)
Japanese 22.9 KB
2024-06-25 09:29
Registration Form
確認書
Japanese 8.2 KB
2024-06-25 09:26
Annual Report
有価証券報告書-第23期(2023/04/01-2024/03/31)
Japanese 1007.8 KB

Automate Your Workflow. Get a real-time feed of all OncoTherapy Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OncoTherapy Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OncoTherapy Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.